CytomX Therapeutics: Barclays Maintains Overweight Rating, PT Raised to $10 from $8

miércoles, 4 de febrero de 2026, 9:20 am ET1 min de lectura
CTMX--

CytomX Therapeutics: Barclays Maintains Overweight Rating, PT Raised to $10 from $8

CytomX Therapeutics: Barclays Maintains Overweight Rating, PT Raised to $10 from $8

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios